X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20174) 20174
Book Chapter (135) 135
Newsletter (81) 81
Book / eBook (37) 37
Magazine Article (30) 30
Web Resource (11) 11
Conference Proceeding (7) 7
Dissertation (7) 7
Newspaper Article (5) 5
Book Review (4) 4
Publication (3) 3
Reference (3) 3
Transcript (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13933) 13933
animals (10593) 10593
mice (6073) 6073
female (5072) 5072
proteins (4556) 4556
recombinant fusion proteins - therapeutic use (4247) 4247
male (4141) 4141
recombinant fusion proteins - genetics (3446) 3446
immunology (3386) 3386
biotechnology & applied microbiology (3101) 3101
recombinant fusion proteins - metabolism (2808) 2808
expression (2685) 2685
biochemistry & molecular biology (2380) 2380
medicine, research & experimental (2364) 2364
research (2327) 2327
recombinant proteins (2289) 2289
oncology (2249) 2249
gene expression (2161) 2161
cancer (2042) 2042
analysis (1940) 1940
health aspects (1938) 1938
middle aged (1868) 1868
recombinant fusion proteins - immunology (1817) 1817
recombinant proteins - genetics (1782) 1782
adult (1712) 1712
research article (1705) 1705
biotechnology (1644) 1644
cell biology (1636) 1636
recombinant proteins - metabolism (1624) 1624
amino acid sequence (1592) 1592
molecular sequence data (1576) 1576
multidisciplinary sciences (1573) 1573
antibodies, monoclonal - therapeutic use (1565) 1565
antibodies (1556) 1556
cell line, tumor (1525) 1525
treatment outcome (1516) 1516
recombinant fusion proteins - pharmacology (1494) 1494
cell line (1484) 1484
vaccines (1470) 1470
mice, inbred balb c (1462) 1462
immunotherapy (1440) 1440
medicine (1422) 1422
pharmacology & pharmacy (1413) 1413
microbiology (1396) 1396
antigens (1394) 1394
in-vivo (1371) 1371
aged (1352) 1352
rats (1341) 1341
hematology (1337) 1337
physiological aspects (1330) 1330
peptides (1311) 1311
cells (1285) 1285
protein (1270) 1270
recombinant fusion proteins - chemistry (1263) 1263
mice, inbred c57bl (1248) 1248
care and treatment (1238) 1238
recombinant fusion proteins - administration & dosage (1236) 1236
therapy (1207) 1207
recombinant proteins - therapeutic use (1158) 1158
fusion protein (1153) 1153
protein binding (1147) 1147
apoptosis (1140) 1140
biology (1113) 1113
disease models, animal (1101) 1101
genetic aspects (1096) 1096
science (1088) 1088
escherichia-coli (1040) 1040
life sciences (1027) 1027
cells, cultured (1003) 1003
transfection (999) 999
recombinant proteins - chemistry (997) 997
genetic vectors (969) 969
enzymes (958) 958
escherichia coli - genetics (924) 924
binding (897) 897
studies (893) 893
immunization (879) 879
viruses (876) 876
enzyme-linked immunosorbent assay (871) 871
genetic engineering (871) 871
in-vitro (863) 863
tumors (862) 862
biochemistry (842) 842
transplantation (835) 835
e coli (834) 834
recombinant proteins - immunology (833) 833
surgery (830) 830
gene therapy (826) 826
genetics & heredity (819) 819
recombinant fusion proteins - biosynthesis (818) 818
cloning (803) 803
genes (799) 799
t cells (796) 796
gene (789) 789
activation (786) 786
time factors (786) 786
recombinant proteins - biosynthesis (783) 783
cytokines (782) 782
escherichia coli (775) 775
cloning, molecular (770) 770
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (13) 13
Gerstein Science - Stacks (10) 10
Engineering & Comp. Sci. - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
UofT at Scarborough - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Not returned (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (20261) 20261
Chinese (77) 77
Japanese (74) 74
French (66) 66
Spanish (41) 41
German (33) 33
Italian (12) 12
Danish (11) 11
Polish (9) 9
Russian (8) 8
Dutch (3) 3
Finnish (3) 3
Hungarian (3) 3
Portuguese (3) 3
Swedish (2) 2
Arabic (1) 1
Croatian (1) 1
Czech (1) 1
Hebrew (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Persian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
Nature (London), ISSN 1476-4687, 2013, Volume 494, Issue 7436, pp. 201 - 206
.... Accordingly, agents that induce autophagy may have broad therapeutic applications. One approach to developing such agents is to exploit autophagy manipulation strategies used by microbial virulence factors... 
Ordered by external client | PATHOGENESIS | LOCALIZES | COMPLEX | PROTEIN | BECLIN-1 | PATHWAY | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | DISEASE | INFECTION | BINDING | Apoptosis Regulatory Proteins - pharmacology | Recombinant Fusion Proteins - pharmacology | Humans | Cell Membrane Permeability | Molecular Sequence Data | Peptide Fragments - pharmacology | Membrane Proteins - pharmacology | Membrane Proteins - therapeutic use | Recombinant Fusion Proteins - metabolism | Autophagy - drug effects | HIV-1 - physiology | nef Gene Products, Human Immunodeficiency Virus - metabolism | Membrane Proteins - metabolism | Beclin-1 | Amino Acid Sequence | HIV-1 - metabolism | Virus Replication - drug effects | Peptide Fragments - metabolism | HIV-1 - drug effects | tat Gene Products, Human Immunodeficiency Virus - genetics | Apoptosis Regulatory Proteins - chemistry | Cells, Cultured | West Nile virus - drug effects | Macrophages - cytology | Recombinant Fusion Proteins - chemistry | Apoptosis Regulatory Proteins - metabolism | Chikungunya virus - drug effects | Peptide Fragments - chemistry | Animals | Membrane Proteins - chemistry | Mice | HeLa Cells | Apoptosis Regulatory Proteins - therapeutic use | tat Gene Products, Human Immunodeficiency Virus - metabolism | Proteins | Peptides | Microscopy | Rodents | Mortality | Amino acids | Infections | Autophagy
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 01/2017, Volume 77, Issue 1, pp. 97 - 106
...) with recombinant human albumin (rAlbumin), is indicated in the treatment of haemophilia B. This narrative review discusses the pharmacological properties and clinical data related to the use of this novel fusion protein, hereafter referred to as rIX-FP... 
HALF-LIFE | PROPHYLAXIS | MANAGEMENT | EFFICACY | SAFETY | PHASE-3 TRIAL | LABEL | PHARMACOLOGY & PHARMACY | TOXICOLOGY | LINKING FACTOR-IX | RIX-FP | Serum Albumin - therapeutic use | Factor IX - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Hemophilia B - drug therapy | Plasma | Medical research | Solvents | Fuses | Peptides | Prophylaxis | Coagulation | Clinical trials | Albumin | Pharmacology | Males | Patients | Bleeding | Coagulation factors | Proteins | Coagulation factor IX | Hemophilia | Adults | Mutation | Children | Adolescents | Fusion protein | Circulation | Half life
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti-vascular endothelial growth factor... 
DA VINCI | Macular Edema [drug therapy surgery] | Growth Factor [therapeutic use] | Humans | RANIBIZUMAB PLUS PROMPT | Receptors, Vascular Endothelial | RANDOMIZED CONTROLLED-TRIAL | Bevacizumab | DEFERRED LASER | Antibodies, Monoclonal, Humanized [therapeutic use] | MEDICINE, GENERAL & INTERNAL | Recombinant Fusion Proteins [therapeutic use] | PEGAPTANIB SODIUM | Angiogenesis Inhibitors [therapeutic use] | Laser Coagulation [methods] | Ranibizumab | QUALITY-OF-LIFE | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | COST-EFFECTIVENESS | Triamcinolone [therapeutic use] | LASER PHOTOCOAGULATION | Randomized Controlled Trials as Topic | Antibodies, Monoclonal [therapeutic use] | Aptamers, Nucleotide [therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Network Meta-Analysis | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy | Quality of Life
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 369, Issue 24, pp. 2313 - 2323
Journal Article
Journal Article
Journal Article